We included 913 patients: 421 KRAS+ patients (G12C 168, other mutations 219, missing 34) and 492 controls (191 DRIVER- and 301 DRIVER+)…Patients were treated by ICI (PD-1/PD-L1 inhibitors)...Among KRAS+ patients, ORR was 26.9% and median PFS was 4.0m in KRAS G12C vs 18.8% and 2.9m in other KRAS types.

Moreover, in the entire population, patients with TP53 mutation (11.0 months vs. 8.5 months, P=0.038), positive PD-L1 expression (9.0 months vs. 8.5 months, P=0.041), or common mutations such as KRAS G12C/G12D/G12V showed better PFS (PFS: 14.5 months vs. 8.0 months, P=0.045)....The patients were divided into two groups according to their timing of receiving immunotherapy, as 105 patients (63.3%) received first-line treatment (1L) and 61 (36.7%) received second-line and above treatment (2L+). The 1L group had better prognosis than the 2L+ group, reflected in ORR (50.5% vs. 29.5%, P=0.001), mPFS (13.5 months vs. 5.0 months, P < 0.001), and mOS (20.0 months vs. 11.0 months, P=0.004)....Bringing immunotherapy to first-line use in NSCLC patients with KRAS mutation might prolong their survival, and combination therapy is a preferable option compared to monotherapy.

This is an observational, retrospective, multicenter study in pts with KRAS-mutant NSCLC treated with ICIs...Regarding overall survival (OS), harboring a G12C mutation was associated with a better OS compared with non-G12C tumors.

One hundred and thirty eight patients with KRASG12C treated with first-line chemo-immunotherapy were included. ORR was 41% (95% confidence interval (CI), 32-41), median PFS was 6.8 months (95%CI, 5.5-10), and median OS was 15 months (95%CI, 11-28).

With a median follow-up for the overall population of 33.82 months, survival analysis showed an improved overall survival (OS) in KRAS G12C tumors compared with tumors harboring KRAS non-G12C mutations (16.9 vs 5.4 months, respectively, p = 0.02).

Patients with KRAS G12C mutation NSCLC treated with ICIs and KRAS G12C patients with TP53 mutation had significantly longer median PFS than those with STK11 mutation (9.0 months vs. 4.3 months, P=0.012).

...therapeutic outcomes of NSCLC patients with KRAS G12C were evaluated....Among KRAS-mutated patients who received immune checkpoint inhibitors (ICIs), the progression-free survival in G12C-positive patients (median, 3.4 months) was similar to that in G12V-positive patients (4.2 months, p = 0.90), but significantly longer than that in G12D- (2.0 months, p = 0.02) and other KRAS mutation-positive patients (2.5 months, p = 0.02)....Among the KRAS-mutated NSCLC patients, G12C-positive tumors showed increased immunogenicity...

This study focuses on possible correlations between the KRAS-G12C mutation and response of patients treated with immunotherapy….In the second group, KRAS G12C mutated patients had a median PFS of 23 months compared with a median PFS of only 5 months among nonmutated patients (HR = 3.28; CI 95% = 0.86-12.5; p value = 0.03).

We identified 137 patients with KRAS-mutant NSCLC treated with chemo-immunotherapy: 45% (62/137) had mutations in KRAS-G12C and 55% harbored non-G12C mutations (17% G12V, 15% G12D, 4% G12A, 4% G12S, 3% G13D). The median OS was 21 and 14 months for G12C and non-G12C patients, respectively (p = 0.24).

69 pts were identified among 264 KRAS mt NSCLC pts...54.89% pts received IT as 1-line (L) treatment, 42.03% as 2L and 3.08% as 3L. Pts without co-mutations had significantly lower response rate (RR) to IT (21.1% vs 50%, p = 0.048)...KRAS G12C was the most frequent KRAS mutation subtype identified (42.03%).

Overall, 28 KRAS mutated patients received immunotherapy as single agent or in combination with chemotherapy in the first-line setting...G12C mutated NSCLC was associated with a better PFS than non-G12C NSCLC (p=0.0384)…

Overall, 28 KRAS mutated patients received immunotherapy as single agent or in combination with chemotherapy in the first-line setting...G12C mutated NSCLC was associated with a better PFS than non-G12C NSCLC (p=0.0384)…

Majority of patients were Caucasian (73%), diagnosed with stage IV (70%) adenocarcinoma (87%), and had a KRAS codon 12 mutation (78%). Twenty percent of patients were treated with immunotherapy. Median overall survival was 28 months in the cohort and patients who received immunotherapy were found to have better survival versus those who did not (33 vs. 22 months, P=0.31).